Company: PTHS
Filing Date: 2025-05-27
Form Type: DEFM14C
Source: 0001140361-25-020509
Chunk: 406

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-27
Form: DEFM14C
Chunk 406
---
 indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for an amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not identify indicators of impairment for the finite-lived intangibles at March 31, 2025.

#### Recent Accounting Pronouncements
The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the audited and unaudited financial statements or disclosures.

<div align='center'>231</div>

TABLE OF CONTENTS

MANAGEMENT FOLLOWING THE MERGER Executive Officers and Directors of the Combined Company Following the Merger The combined company’s board of directors will initially be fixed at seven members, consisting of one director selected by Channel, namely Dr. Richard Malamut, one director who is the intended Chief Executive Officer of the surviving corporation, namely Scott Plesha, four directors selected by LNHC, namely Peter Greenleaf, Matthew Pauls, Todd Davis and Richard Baxter, and one member selected by Nomis Bay, namely Ezra Friedberg. The following table lists the names and ages, as of May 23, 2025, and positions of the individuals who are expected to serve as executive officers and directors of the combined company upon completion of the Merger.

| Name                    |     | Age |     | Position                                        |
| Executive Officers      |     |     |     |                                                 |
| Scott Plesha            |     |  61 |     | Chief Executive Officer, President and Director |
| Francis Knuettel II     |     |  59 |     | Chief Financial Officer                         |
| Non-employee Directors  |     |     |     |                                                 |
| Todd Davis              |     |  64 |     | Chairman of the Board                           |
| Richard Baxter(1)(2)(3) |     |  62 |     | Director                                        |
| Ezra Friedberg(1)       |     |  55 |     | Director                                        |
| Peter Greenleaf         |     |  55 |     | Director                                        |
| Dr. Richard Malamut(2)  |     |  65 |     | Director                                        |
| Matthew